• 1
    D'Amico G, Palgliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence based approach. Semin Liver Dis 1999; 19: 475505.
  • 2
    Hayes PC, Davis JM, Lewis JA, Bouchier IAD. Meta-analysis of value of propranolol in prevention of variceal hemorrhage. Lancet 1990; 336: 1536.
  • 3
    Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997; 25: 6370.
  • 4
    Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. J Hepatol 1997; 26: 31224.
  • 5
    D'Amico G, Palgliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 33254.
  • 6
    Bosch J, Masti R, Kravetz D, et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984; 4: 12005.
  • 7
    Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices, and variceal bleeding. Hepatology 1985; 5: 41924.
  • 8
    Stanley AJ, Robinson I, Forrest EH, Jones AL, Hayes PC. Haemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis. Q J Med 1998; 91: 1925.
  • 9
    Merkel C, Bolognesi M, Sacerdoti D, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 32: 9304.
  • 10
    Feu F, Garcia-Pagan JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal hemorrhage in patients with cirrhosis. Lancet 1995; 346: 10569.
  • 11
    Escorsell A, Bordas JM, Castaneda B, et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 2000; 31: 10617.
  • 12
    Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345: 64755.
  • 13
    Boyer T. Pharmacologic treatment of portal hypertension: past, present, and future. Hepatology 2001; 34: 8349.
  • 14
    Imperial TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 2001; 33: 8027.
  • 15
    Grace N, Bhattacharya K. Pharmacologic therapy of portal hypertension and variceal hemorrhage. Clin Liver Dis 1997; 1: 5975.
  • 16
    Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decision Making 1983; 3: 41958.
  • 17
    Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decision Making 1993; 13: 32238.
  • 18
    Lo GH, Lai KH, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding. Hepatology 2000; 32: 6602.
  • 19
    Patch D, Sabin CA, Goulis J, et al. A randomized controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002; 123: 10139.
  • 20
    Lo GH, Chen WC, Chen MH, et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology 2002; 123: 72834.
  • 21
    Gournay J, Masliah C, Martin T, Perrin D, Galmiche JP. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000; 31: 123945.
  • 22
    Villanueva C, Balanzo J, Novella MT, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334: 16249.
  • 23
    Garcia-Pagan JC, Feu F, Bosch J, Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. Ann Intern Med 1991; 114: 86973.
  • 24
    Albillos A, Garcia-Pagan JC, Iborra J, et al. Propanolol plus prazosin compared with propanolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology 1998; 115: 11623.
  • 25
    Nevens F, Bustami R, Scheys I, Lesaffre E, Fevery J. Variceal pressure is a factor predicting the risk of first variceal bleeding. Hepatology 1998; 27: 159.
  • 26
    Laine L, Stein C, Sharma V. Randomized comparison of ligation versus ligation plus sclerotherapy in patients with bleeding esophageal varices. Gastroenterology 1996; 110: 52933.
  • 27
    DeFranchis R, Primignani M. Endoscopic treatments for portal hypertension. Semin Liver Dis 1999; 19: 43955.
  • 28
    Drug Topics Red Book. Montvale: Medical Economics Company, 2002; 392: 510.
  • 29
    Gralnek IM, Jensen DM, Kovacs TO, et al. The economic impact of esophageal variceal hemorrhage: cost-effectiveness implications of endoscopic therapy. Hepatology 1999; 29: 4450.
  • 30
    Gralnek IM, Jensen DM, Kovacs TO, et al. Economic impact of esophageal variceal hemorrhage. Hepatology 1999; 29: 4450.
  • 31
    Zaman A, Goldberg-Arnold RJ, Pettit KG, et al. Cost of treating an episode of variceal bleeding in a VA setting. Am J Gastroenterol 2000; 95: 132330.
    Direct Link:
  • 32
    Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford: Oxford University Press, 1997.
  • 33
    Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: GoldMR, Siegel JE, Russell LB, WeinsteinMC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996: 21446.
  • 34
    North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1988; 319: 9839.
  • 35
    Rigau J, Bosch J, Bordas JM, et al. Endoscopic measurement of variceal pressure in cirrhosis: correlation with portal pressure and variceal hemorrhage. Gastroenterology 1989; 96: 87380.
  • 36
    El Atti EA, Nevens F, Bogaerts K, Verbeke G, Fevery J. Variceal pressure is a strong predictor of variceal hemorrhage in patients with cirrhosis as well as in patients with non-cirrhotic portal hypertension. Gut 1999; 45: 61821.
  • 37
    Luketic VA. Management of portal hypertension after variceal hemorrhage. Clin Liver Dis 2001; 5: 677707.
  • 38
    Keiding S, Vilstrup H. Intrahepatic heterogeneity of hepa tic venous pressure gradient in human cirrhosis. Scand J Gastroenterol 2002; 37: 9604.
  • 39
    Hansen EF, Bendtsen F, Brinch K, Moller S, Hendriksen JH, Becker U. Endoscopic Doppler ultrasound for measurement of azygos blood flow. Scand J Gastroenterol 2001; 363: 31825.
  • 40
    Iwao T, Toyonaga A, Oho K. Value of Doppler ultrasound parameters of portal vein and hepatic artery in the diagnosis of cirrhosis and portal hypertension. Am J Gastroenterol 1997; 92: 10127.